Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EPHX1 | P07099 | 2/20 | 0.52 |
| ▸ | HTT | P42858 | 2/20 | 0.48 |
| ▸ | MEN1 | O00255 | 1/20 | 0.48 |
| ▸ | THRB | P10828 | 1/20 | 0.48 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.48 |
| ▸ | MAPT | P10636 | 1/20 | 0.48 |
| ▸ | TSHR | P16473 | 3/20 | 0.42 |
| ▸ | CES2 | O00748 | 2/20 | 0.40 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.38 |
| ▸ | PLA2G2C | Q5R387 | 1/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.38 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.38 |
| ▸ | USP2 | O75604 | 1/20 | 0.38 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.37 |
| ▸ | CES1 | P23141 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17479935 | 0.98 | EPHX1 (0.56) | EPHX1HTTMEN1THRBKMT2A | |
| SCHEMBL17479925 | 0.98 | EPHX1 (0.56) | EPHX1HTTMEN1THRBKMT2A | |
| SCHEMBL17479934 | 0.98 | EPHX1 (0.56) | EPHX1HTTMEN1THRBKMT2A | |
| SCHEMBL17479926 | 0.98 | EPHX1 (0.56) | EPHX1HTTMEN1THRBKMT2A | |
| SCHEMBL14759886 | 0.98 | EPHX1 (0.56) | EPHX1HTTMEN1THRBKMT2A | |
| SCHEMBL8378703 | 0.98 | EPHX1 (0.56) | EPHX1HTTMEN1THRBKMT2A | |
| SCHEMBL17479927 | 0.98 | EPHX1 (0.56) | EPHX1HTTMEN1THRBKMT2A | |
| SCHEMBL19418439 | 0.98 | EPHX1 (0.56) | EPHX1HTTMEN1THRBKMT2A | |
| SCHEMBL21634574 | 0.98 | HTT (0.52) | EPHX1HTTMEN1THRBKMT2A | |
| SCHEMBL27174198 | 0.98 | EPHX1 (0.56) | EPHX1HTTMEN1THRBKMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0576445-B1 | A COMPOSITION FOR USE IN WASHING AND CLEANSING VULCANIZATION MOLDS | SAN MARTINO SPA (IT) | 1996-05-15 | — | — | EP | claimed |
| WO-1992016346-A1 | A COMPOSITION FOR USE IN WASHING AND CLEANSING VULCANIZATION MOLDS | SILVANI ANTINCENDI S.P.A (IT) | 1992-10-01 | — | — | WO | claimed |
| CN-118382612-A | Method for producing blocked isocyanate compound and method for producing isocyanate compound | 旭化成株式会社 | 2024-07-23 | — | — | CN | disclosed |
| EP-3512842-B1 | INDOLE DERIVATIVES AS ESTROGEN RECEPTOR DEGRADERS | ARVINAS INC (US) | 2024-01-17 | — | — | EP | disclosed |
| EP-3689868-B1 | TETRAHYDRONAPHTHALENE AND TETRAHYDROISOQUINOLINE DERIVATIVES AS ESTROGEN RECEPTOR DEGRADERS | ARVINAS OPERATIONS INC (US) | 2023-09-27 | — | — | EP | disclosed |
| CN-115190901-A | Carbodiimide composition, curing agent composition, coating composition, and resin cured product | 旭化成株式会社 | 2022-10-14 | — | — | CN | disclosed |
| EP-3728237-B1 | SUBSTITUTED THIOPHENYLURACILS , THEIR SALTS AND USE OF SAID COMPOUNDS AS HERBICIDAL AGENTS | SYNGENTA CROP PROTECTION AG (CH) | 2022-02-09 | — | — | EP | disclosed |
| US-20210214316-A1 | ANTI-CANCER NUCLEAR HORMONE RECEPTOR-TARGETING COMPOUNDS | SAGARD HOLDINGS MANAGER LP, AS ADMINISTRATIVE AGENT (CA) | 2021-07-15 | — | — | US | disclosed |
| WO-2020023851-A1 | BIFUNCTIONAL SUBSTITUED PYRIMIDINES AS MODULATORS OF FAK PROTEOLYSE | YALE UNIVERSITY (US) | 2020-01-30 | — | — | WO | disclosed |
| WO-2018119357-A1 | COMPOUNDS AND METHODS FOR THE TARGETED DEGRADATION OF ENHANCER OF ZESTE HOMOLOG 2 POLYPEPTIDE | Arvinas, Inc. (US) | 2018-06-28 | — | — | WO | disclosed |
| WO-2018102067-A2 | TAU-PROTEIN TARGETING PROTACS AND ASSOCIATED METHODS OF USE | Arvinas, Inc. (US) | 2018-06-07 | — | — | WO | disclosed |
| WO-2018102725-A1 | TETRAHYDRONAPHTHALENE AND TETRAHYDROISOQUINOLINE DERIVATIVES AS ESTROGEN RECEPTOR DEGRADERS | Arvinas, Inc. (US) | 2018-06-07 | — | — | WO | disclosed |
| WO-2018071606-A1 | COMPOUNDS AND METHODS FOR THE TARGETED DEGRADATION OF ANDROGEN RECEPTOR | Arvinas, Inc. (US) | 2018-04-19 | — | — | WO | disclosed |
| CN-103936763-A | Oxazolidinone compound as well as preparing method and purpose thereof | SHANGHAI INST MATERIA MEDICA | 2014-07-23 | — | — | CN | disclosed |
| EP-0576445-B1 | A COMPOSITION FOR USE IN WASHING AND CLEANSING VULCANIZATION MOLDS | SAN MARTINO SPA (IT) | 1996-05-15 | — | — | EP | disclosed |
| US-5468422-A | Composition for use in washing and cleansing vulcanization molds | SILVANI ANTINCEDI (IT) | 1995-11-21 | — | — | US | disclosed |
| EP-0576445-A1 | A COMPOSITION FOR USE IN WASHING AND CLEANSING VULCANIZATION MOLDS. | SILVANI ANTINCENDI SPA (IT) | 1994-01-05 | — | — | EP | disclosed |
| WO-1992016346-A1 | A COMPOSITION FOR USE IN WASHING AND CLEANSING VULCANIZATION MOLDS | SILVANI ANTINCENDI S.P.A (IT) | 1992-10-01 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210214316-A1 | ANTI-CANCER NUCLEAR HORMONE RECEPTOR-TARGETING COMPOUNDS | NCOA1, NCOR1, NCOA3 | EPHX1 4120/4885HTT 3436/4885MEN1 2250/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.